Cargando…
1333 Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year
Autores principales: | Wald, Anna, Warren, Terri, Fife, Kenneth, Tyring, Stephen, Lee, Patricia, Van Wagoner, Nicholas, Bernstein, David, Flechtner, Jessica B., Magaret, Amalia, Morris, Amy, Hetherington, Seth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781666/ http://dx.doi.org/10.1093/ofid/ofu051.150 |
Ejemplares similares
-
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial
por: Bernstein, David I., et al.
Publicado: (2017) -
1154 Host and Pathogen Genetics Modulate HSV-1 Severity
por: Ramchandani, Meena, et al.
Publicado: (2014) -
Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy
por: Heineman, Thomas, et al.
Publicado: (2017) -
Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo
por: Heineman, Thomas C, et al.
Publicado: (2017) -
1224 Defining herpes simplex virus type 2 sequence heterogeneity using next generation sequencing
por: Johnston, Christine, et al.
Publicado: (2014)